Astrana Health, Inc. · Management Consulting Services

ASTH

Moderate riskNext report: Around Nov 5 (est.)

View price ↗

The short version

A profitable company with growing sales. Institutions are adding.

Going well

Sales up 49% in the latest quarter vs a year ago
Profitable every year for 10 years
Sales up 56% last year

Money moves

No insider buying or selling in the last 30 days
Institutions added 7.4% to their holdings in the quarter ending June 2026 (135 bought, 66 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$37.23-0.5% that day

Company value: $2.1B; Share price times all shares
Price vs profit (P/E): 44.9x; You pay about $45 for each $1 of yearly profit
Price vs sales: 0.54x; Company value is 0.54 times a year of sales
Cash vs value: 19%; Cash as a share of company value
Debt vs value: 50%; Debt as a share of company value

From ASTH's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$972.5M+49% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $3.8B, up 59% from the 12 months before. Over 5 years, sales grew about 36% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of ASTH. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +59% a yearProfit margin1%Last 12 months: 1.1%P/E at the end40xToday: 44.9x. Many steady companies trade at 12x to 25xShare count change+3% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$14.3B

Profit in 5 years$143M

Price these guesses point to$88.36+137% vs $37.23 todayAbout +19% a year, before dividends

What today's price needs: with a 1% margin and a 40x P/E, sales would have to grow about 9.4% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

2/6Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.3.2%
MissDebt under half of equityNot relying on borrowed money.1.33x equity
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.0.8%
PassProfitable every yearSteady profits, not one good year.10 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$104.5M
MissShare count not growingNot diluting owners. Falling means buybacks.+8.3% in 3 years

Revenue: $3.2B; +56.4% vs prior year
5-year growth: +35.9%/yr; revenue, per year
Total debt: $1.0B; 1.33x equity
Current ratio: 1.40x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.